Plain-English translation of NCT06705998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial of a new medication called BAR502 designed to help treat a liver condition. Researchers want to understand how safe the medication is, how your body processes it, and what effects it has — all in healthy volunteers first, before it is ever tested in patients who have the disease it may treat.
Before any new medication can be tested in patients who are sick, it must first be carefully studied in healthy people to make sure it is safe and that the body can tolerate it. This trial fills that essential first step.
You likely qualify if…
You likely don't qualify if…
The trial has two parts. In Part A, you will visit the clinic and receive either one dose of the medication or placebo (a dummy pill), then have blood tests and vital signs checked over several hours. In Part B, if certain doses proved safe, you will take the medication once daily for 14 days at home, with follow-up visits to the clinic. The entire study lasts several weeks and involves blood draws, heart monitor readings, and regular check-ins with the research team.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Switzerland
Phase
Safety & dosing
Sponsor
BAR Pharmaceuticals s.r.l.
Enrollment target
~52 participants
Started
December 2024
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Stefano Fiorucci, MD
CROSS Research S.A., Phase I Unit
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.